1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Euthymics expands series A financing to work on 'next generation Straterra'

 
• By Sukaina Virji

Euthymics Bioscience has added $4 million to its series A financing to fund preclinical development of its second product candidate, EB-1020, a non-stimulant for adult attention deficit hyperactivity disorder (ADHD). The product is "a different drug altogether" from Shire's non-stimulant ADHD drug Intuniv (guanfacine), Euthymic's president and CEO, Anthony McKinney, told Scrip.

Euthymics Bioscience has added $4 million to its series A financing to fund preclinical development of its second product candidate, EB-1020, a non-stimulant for adult attention deficit hyperactivity disorder (ADHD). The product is "a different drug altogether" from Shire's non-stimulant ADHD drug Intuniv (guanfacine), Euthymic's president and CEO, Anthony McKinney, told Scrip.

"Members of our leadership team were involved in the development of the first non-stimulant developed for ADHD, Lilly's Straterra (atomoxetine), and we've built on the lessons from that. We have...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

Lilly To Diversify Pain Pipeline With SiteOne Acquisition

 
• By Joseph Haas

Deal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne.

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

More from Therapeutic Category

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

GlycoEra’s Series B Cash Will Fund Efforts To Take On FcRn Inhibitor Class

 
• By Joseph Haas

GlycoEra unveiled a $130m series B financing, saying the proceeds would enable it to take its first clinical candidate through proof-of-concept in autoimmune diseases.

Ascentage Broadens Horizons As Pipeline Shows Renewed Promise

 
• By Xu Hu

Ascentage will share at ASCO new clinical data on its Bcl-2 inhibitor lisaftoclax, part of the Chinese firm's novel pipeline, on which its CEO shared with Scrip plans and strategy, along with some views on the use of RWD in China.